NeuroSense Therapeutics (NASDAQ:NRSN) CEO Acquires $200,000.00 in Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CEO Alon Ben-Noon bought 250,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief executive officer directly owned 4,534,233 shares in the company, valued at approximately $3,627,386.40. This represents a 5.84% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ NRSN traded up $0.01 during trading on Wednesday, hitting $0.71. 228,051 shares of the company were exchanged, compared to its average volume of 174,519. The company has a market cap of $22.95 million, a price-to-earnings ratio of -1.31 and a beta of 1.56. NeuroSense Therapeutics Ltd. has a 1 year low of $0.63 and a 1 year high of $2.52. The firm’s fifty day moving average price is $0.78 and its 200 day moving average price is $0.86.

Institutional Investors Weigh In On NeuroSense Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC raised its position in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics in the second quarter worth $54,000. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics in the third quarter worth $26,000. Finally, Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics in the fourth quarter worth $77,000. 1.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NRSN. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. Finally, Roth Mkm started coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, NeuroSense Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.